A new study, released on the bioRxiv* preprint server, shows that rapamycin, an immunosuppressive drug used in some cancers, and
Continue reading »
Home ยป
DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19
RedHill Biopharma Ltd. ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board
Continue reading »
PIM-2 protein kinase regulates T-cell activity differently than PIM-1 or PIM-3 isoform
The PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity, while PIM-1 and PIM-3 are positive
Continue reading »